A Scalable Manufacturing Platform For The Purification Of Stem Cell Derived Exosomes

The purification of extracellular vesicles (EVs) and exosomes for clinical applications presents unique challenges, particularly concerning scalability and maintaining product quality. Traditional methods have struggled with low recoveries and filter fouling, hindering the industrialization of these promising cell-free therapies.

This application note introduces a novel, scalable manufacturing platform for purifying stem cell-derived exosomes, a result of a collaboration between RoosterBio and Cytiva. The platform demonstrates remarkable success in achieving high EV recovery and enhanced purity while effectively clearing impurities such as protein, nucleic acids, and albumin, all without compromising the critical quality attributes and potency of the EVs.

Dive into the full application note for a detailed look at this innovative manufacturing platform.